Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hookipa Biotech
Hookipa Biotech
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Drug Delivery
Hookipa achieves $10 million towards immunotherapy for KRAS-mutated cancers
“We’re excited to advance the HB-700 program, our third in oncology, and we’re eager to explore the potential of our technology in addressing another unmet need in cancer.”
Regulatory
FDA accepts HOOKIPA’s IND application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase I/II trial to commence by early 2023
Research & Development
Hookipa and Gilead amend HIV immunotherapy agreement
Under the original agreement, Gilead would assume rights for further development following a joint research phase
Research & Development
Hookipa announces clinical collaboration with Merck USA
The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as treatment for patients with advanced head and neck squamous cell carcinoma
Research & Development
Hookipa Gilead collaboration reaches major milestones
The license agreement to focus on HBV and HIV has now delivered 24 research-grade vectors
Recruitment
Dr Jan van de Winkel joins Hookipa as Chairman of its Board of Directors
Reinhard Kandera appointed CFO of Hookipa Biotech
Subscribe now